Marcio Lasaro

Director Business Development and Licensing at Boehringer Ingelheim

Presenter

Boehringer Ingelheim is a world-leading, research-driven biopharmaceutical company. Making new and better medicines for patients is at the heart of what we do. Independent and family-owned, we have the freedom to pursue our long-term vision, identifying the health challenges of the future and targeting those areas of need where we can do the most good.

In 2023 Boehringer Ingelheim achieved net sales of 25.6 billion euros, with an industry-leading investment in R&D of 22.5% of net sales. Our vision is powered by innovation. And our industry-leading investment in R&D drives this, with a portfolio that is anchored by more than 60 new medical entities, enabling the next generation of breakthrough medicines.

We realize even more scientific opportunities by leveraging the wealth of complementary expertise across the global community of scientists to bring critical diversity to innovation. By working together we can learn more, do more and achieve more and accelerate the delivery of the next breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Research Beyond Borders: AAV, gene therapy, regenerative medicine, emerging science: Open to new and disruptive ideas in uncharted therapeutic spaces to treat diseases for which there are no effective therapies.